Cancer of Liver

3

Review clinical trials related to Cancer of Liver. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

Participants needed: 50,000
Trial details
Biological sex: AllType: ObservationalSponsor: Massive Bio, Inc.Updated: Oct 28, 2025Locations: 68Duration: 36 Months
Eligibility criteria

Pts with solid and hematological malignancies; [+2]

ECOG PS > 2; [+2]

Status: Recruiting

Prospective Cohort of Patients With Hepatocellular Carcinoma in France

Hepatocellular carcinoma (HCC) occurs in 90% of cirrhosis primary liver cancers. In France, 8,500 new cases of HCC occur each year, and about 8,000 deaths per year are related to this cancer. The 5-year survival rate is 10%, one of the lowest survival rates of all cancer types. HCC raises a number of major challenges: HCC is discovered at a curable stage in only 25% of cases, reflecting the marked delay in the diagnosis of early stages. The state of knowledge about HCC is well behind that of other cancers (no biomarker, complex carcinogenesis, influence of the aetiology, poorly valorised data, etc.). Rapid technological progress requires large-scale studies to evaluate new diagnostic and therapeutic modalities. The CHIEF project constitutes a common basis knowledge for research project using prospectively collected data in patients with HCC, regardless of the cause and stage of the cancer. This project is a Multicentre longitudinal observational study of patients with HCC with prospective data collection on inclusion and patient follow-up. Constitution of a biological resources collection. 5,000 patients will be included over 2 years with a follow-up of patients of 5 years.

Participants needed: 5,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Centre Hospitalier Universitaire, AmiensUpdated: Jun 10, 2025Locations: 1
Eligibility criteria

New cases of HCC [+2]

Associated serious condition threatening life in the short term (with the except... [+1]

Status: Not yet recruiting

Wet Heparinized Suction for Abdominal Cancer

The purpose of this research is to compare the amount and quality of tissue obtained by EUS-FNB when the device is flushed with an anticoagulant or "blood thinner" vs. saline a salt water solution as well as the use of a microsieve in order for the doctor to look at the tissue to check the acceptability of the specimens before sending for analysis. You will be randomly assigned (like a flip of a coin) to have either the blood thinner or the salt water solution placed within the needle being used to sample your abdominal tumor and to have either a sieve used or not. You will be one of 42 participants enrolled in this data collection study which includes 1 sites in the United States.

Participants needed: 42
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: H. Lee Moffitt Cancer Center and Research InstituteUpdated: Apr 22, 2025Locations: 1
Eligibility criteria

Age ≥ 18 year [+4]

Age < 18 years [+9]